ResMed (NYSE: RMD and ASX: RMD.AX) is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.
The ResMed Team
Business success can be said to depend upon three key fundamentals—people, products and profits—and that without a good team the other two just aren’t possible. ResMed has a team of over 3,000 people based around the globe. Everyone in our team is working to help the millions of people suffering from SDB and other respiratory disorders, to educate the medical community and public about the dangers of untreated SDB, to strengthen our global operations and to deliver the very best products to our SDB patients. In addition, we have a senior management team with extensive experience in the SDB field and the medical device industry in general.
The term “sleep-disordered breathing” includes a spectrum of respiratory disorders ranging in severity from snoring to OSA. OSA occurs when the airway temporarily collapses during sleep, preventing or restricting breathing for up to ten seconds or more. Such events can occur several hundred times a night severely disrupting sleep.
Untreated OSA can severely affect quality of life, health and mortality. Clinical research shows that it is linked strongly to a range of serious, even life-threatening, chronic diseases such as stroke, heart failure, hypertension, diabetes, obesity and coronary heart disease.